IE32866L - Antibiotic complex - Google Patents
Antibiotic complexInfo
- Publication number
- IE32866L IE32866L IE690769A IE76969A IE32866L IE 32866 L IE32866 L IE 32866L IE 690769 A IE690769 A IE 690769A IE 76969 A IE76969 A IE 76969A IE 32866 L IE32866 L IE 32866L
- Authority
- IE
- Ireland
- Prior art keywords
- axenomycine
- meoh
- spectrum
- complex
- components
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G11/00—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F7/00—Shielded cells or rooms
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1,219,709. The antibiotic axenomycine. SOC. FARMACEUTICI ITALIA. 6 June, 1969 [11 June, 1968], No. 28849/69. Heading C2A. The novel antibiotic axenomycine, also named F.I. 2604, is produced by cultivating Streptomyces lisandri n. sp., I.P.V 1951, I.M.R.U. 3935, I.M.I. 137178, or an axenomycine-producing strain thereof, under aerobic conditions in an aqueous medium containing assimilable sources of carbon and nitrogen and mineral salts, and isolating the axenomycine from the cultivated medium. The cultivation is preferably carried out at 23-37‹ C. and pH 6-9 for 60-160 hours. Axenomycine is a complex of two components, axenomycines A and B. The complex and its components are amorphous yellowish-white substances, soluble in methyl, ethyl and propyl alcohol, sparingly soluble in water, ethyl acetate, acetone and chloroform, and insoluble in benzene and petroleum ether. They reduce Fehling's solution and ammoniacal silver nitrate, give a positive reaction with tetrazole blue and a weakly positive Molisch reaction. They give negative reactions with ferric chloride, the aniline phthalate test for aldoses and the naphthoresorcinol test for ketoses. Axenomycine A has the following characteristics: elementary analysis, 61.74% C, 8.52% H, 28.87% O; molecular weight 1451.3; melting point 127-142‹ C. to give a transparent reddish gel; [α]23‹ D = + 10À5‹ (C = 0.9 in MeOH); Rf = 0.49 on silica gel at pH 7.0 using n. butanol: acetic acid: water = 4: 0.5: 1; U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265-268 mÁ; I.R. spectrum in a KBr disc has peaks at 2.94, 3À44, 5.78, 6.00, 6.16, 6.24, 6.88, 7.25, 7.41, 8.61, 8.85, 9.35, 10.00, 10.40, 10.95, 11.8 and 12À5 Á. Axenomycine B has the characteristics: elementary analysis, 62.8% C., 8.58% H, 27.8% O; molecular weight 1330.2; melting point 122- 140‹ C.; [α]23‹ D = + 5‹ (C = 0.9 in MeOH); Rf = 0À61 on silica gel at pH 7À0 using n. butanol: acetic acid: water = 4À0 : 0À5: 1; U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265- 268 mÁ; I.R. spectrum in a KBr disc has peaks at 2.94, 3À40, 5.82, 6.00, 6.16, 6.24, 6.86, 7.25, 7.41, 8.60, 8.85, 9.35, 10.00, 10.40, 10.98, 11.8, and 12À5 Á. The antibiotic complex may be extracted from the separated mycelium with e.g. methanol, or from the whole broth with a water-immiscible solvent, and purified by precipitation with a non-solvent followed by counter-current distribution. The two components may be separated by chromatography on a silica gel column at pH 7.0, developing with BuOH: HAc: H 2 O, 4: 0À5: 1 by volume. The antibiotics have anthelmintic, antiprotozoal and antifungal activity. Pharmaceutical compositions comprise axenomycine complex or one of its components A or B together with a pharmaceutically acceptable vehicle.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1757068 | 1968-06-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE32866L true IE32866L (en) | 1969-12-11 |
| IE32866B1 IE32866B1 (en) | 1973-12-28 |
Family
ID=11150434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE769/69A IE32866B1 (en) | 1968-06-11 | 1969-06-06 | Antibiotic complex |
Country Status (16)
| Country | Link |
|---|---|
| AT (1) | AT285817B (en) |
| BE (1) | BE734341A (en) |
| BR (1) | BR6909580D0 (en) |
| CH (1) | CH506619A (en) |
| CS (1) | CS178807B2 (en) |
| DE (1) | DE1929107C3 (en) |
| DK (1) | DK120716B (en) |
| ES (1) | ES368198A1 (en) |
| FR (1) | FR2010640A1 (en) |
| GB (1) | GB1219709A (en) |
| IE (1) | IE32866B1 (en) |
| IL (1) | IL32358A (en) |
| NL (1) | NL153271B (en) |
| NO (1) | NO127927B (en) |
| SE (1) | SE354483B (en) |
| YU (1) | YU34212B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1044819B (en) * | 1970-05-04 | 1980-04-21 | Farmaceutici Italia | ANTIBIOTIC COMPOUND |
-
1969
- 1969-05-30 NL NL696908269A patent/NL153271B/en unknown
- 1969-06-06 FR FR6918667A patent/FR2010640A1/fr not_active Withdrawn
- 1969-06-06 IE IE769/69A patent/IE32866B1/en unknown
- 1969-06-06 GB GB28849/69A patent/GB1219709A/en not_active Expired
- 1969-06-06 CS CS6900004032A patent/CS178807B2/en unknown
- 1969-06-06 IL IL32358A patent/IL32358A/en unknown
- 1969-06-09 BR BR209580/69A patent/BR6909580D0/en unknown
- 1969-06-09 AT AT544069A patent/AT285817B/en not_active IP Right Cessation
- 1969-06-09 SE SE08124/69A patent/SE354483B/xx unknown
- 1969-06-09 DE DE1929107A patent/DE1929107C3/en not_active Expired
- 1969-06-09 NO NO02366/69A patent/NO127927B/no unknown
- 1969-06-09 DK DK310069AA patent/DK120716B/en unknown
- 1969-06-09 YU YU1444/69A patent/YU34212B/en unknown
- 1969-06-10 BE BE734341D patent/BE734341A/xx unknown
- 1969-06-10 CH CH882169A patent/CH506619A/en not_active IP Right Cessation
- 1969-06-10 ES ES368198A patent/ES368198A1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE32866B1 (en) | 1973-12-28 |
| CS178807B2 (en) | 1977-10-31 |
| IL32358A (en) | 1972-11-28 |
| IL32358A0 (en) | 1969-08-27 |
| DE1929107A1 (en) | 1970-02-19 |
| CH506619A (en) | 1971-04-30 |
| NL6908269A (en) | 1969-12-15 |
| YU144469A (en) | 1978-06-30 |
| AT285817B (en) | 1970-11-10 |
| BR6909580D0 (en) | 1973-04-19 |
| FR2010640A1 (en) | 1970-02-20 |
| NO127927B (en) | 1973-09-03 |
| SE354483B (en) | 1973-03-12 |
| DK120716B (en) | 1971-07-05 |
| GB1219709A (en) | 1971-01-20 |
| DE1929107C3 (en) | 1978-10-12 |
| ES368198A1 (en) | 1971-05-01 |
| YU34212B (en) | 1979-02-28 |
| DE1929107B2 (en) | 1978-02-09 |
| BE734341A (en) | 1969-12-10 |
| NL153271B (en) | 1977-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grove et al. | The cytotoxicity of some transformation products of diacetoxyscirpenol | |
| US3780173A (en) | Partricin methyl ester | |
| Carter et al. | Streptothricin. I. Preparation, Properties and Hydrolysis Products1 | |
| IE32866B1 (en) | Antibiotic complex | |
| GB1349179A (en) | Antibiotic | |
| Kettner et al. | Dactylarin, a new antiprotozoal antibiotic from Dactylaria lutea | |
| GB1038242A (en) | Bleomycin and processes for preparation thereof | |
| GB1392364A (en) | Antibiotics | |
| GB1116280A (en) | Antibiotic a28829 | |
| KITAGAWA et al. | Studies on viomycin. VIII. Selective modifications of the terminal amino groups of viomycin | |
| Sano et al. | Iyomycin, A New Antitumor Antibiotic from Streptomyces. III Isolation and Properties of Iyomycin B | |
| US3089816A (en) | Lemacidine and process for its manufacture | |
| TAKANI et al. | Studies on constituents of medicinal plants. XIX. Constituents of Schizandra nigra Max.(3) | |
| GB1433417A (en) | Antibiotic a-2315 and process for preparation thereof | |
| GB1310712A (en) | Method for preparing monoacyl derivatives of antibiotic t-2636c | |
| GB1292010A (en) | A new antibiotic, its production and its use | |
| GB1378414A (en) | Antibiotic compound and its preparation | |
| GB1156390A (en) | Polyoxin Antibiotics and process for preparing the same | |
| SAWADA et al. | Studies on the β-lysine peptide. IV. Preparation of semi-synthetic racemomycins and their antimicrobial activities | |
| GB1314983A (en) | Antibiotic substance and method of producing same | |
| GB1212741A (en) | A method for producing an antibiotic b-2847 | |
| IE36010B1 (en) | Antibiotic compound | |
| GB1356723A (en) | Antibiotic sf-1293 substance and its production and uses | |
| GB1084364A (en) | ||
| GB1389065A (en) | Process for isolating an antibiotic with both antiprotozoan and cancerostatic activities |